Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.230
Neutral
RSI(14)
73.011
Buy
STOCH(KDJ)(9,3,3)
80.877
Neutral
ATR(14)
2.997
High Vlolatility
CCI(14)
76.545
Neutral
Williams %R
15.948
Overbought
TRIX(12,20)
0.812
Sell
StochRSI(14)
0.000
Sell
Glaukos Corp
GKOS116.220USD
-0.420-0.36%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
6.67BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Glaukos Corp
Currency: USD Updated: 2025-12-26Key Insights
Glaukos Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 121.07.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Glaukos Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
16
analysts
Buy
Current Rating
121.071
Target Price
+11.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Glaukos Corp Highlights
StrengthsRisks
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.57% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 383.48M.
Undervalued
The company’s latest PE is -75.27, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.34M shares, increasing 0.38% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 68.06K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Glaukos Corp is 7.89, ranking 60/207 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 133.54M, representing a year-over-year increase of 38.14%, while its net profit experienced a year-over-year increase of 24.19%.
Score
Financials
8.43
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.31
Operational Efficiency
7.60
Growth Potential
8.80
Shareholder Returns
7.33
Glaukos Corp's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Glaukos Corp is 7.24, ranking 109/207 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -75.27, which is -79.38% below the recent high of -15.52 and -0.76% above the recent low of -75.84.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 9/207
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Glaukos Corp is 8.38, ranking 45/207 in the Healthcare Equipment & Supplies industry. The average price target for Glaukos Corp is 120.00, with a high of 165.00 and a low of 72.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
121.071
Target Price
+11.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Glaukos Corp
GKOS
16
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Glaukos Corp is 9.22, ranking 16/207 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 121.55 and the support level at 107.49, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
116.468
Sell
MA10
114.234
Buy
MA20
110.945
Buy
MA50
96.699
Buy
MA100
92.142
Buy
MA200
93.975
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Glaukos Corp is 10.00, ranking 1/207 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 106.80%, representing a quarter-over-quarter increase of 0.31%. The largest institutional shareholder is The Vanguard, holding a total of 6.03M shares, representing 10.50% of shares outstanding, with 0.83% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Wellington Management Company, LLP
State Street Investment Management (US)
AllianceBernstein L.P.
Burns (Thomas William)
Geode Capital Management, L.L.C.
Columbia Threadneedle Investments (US)
Westfield Capital Management Company, L.P.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Glaukos Corp is 5.46, ranking 77/207 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.68
VaR
+4.14%
240-Day Maximum Drawdown
+53.68%
240-Day Volatility
+57.66%
Return
Best Daily Return
60 days
+13.89%
120 days
+13.89%
5 years
+25.36%
Worst Daily Return
60 days
-8.83%
120 days
-8.83%
5 years
-21.41%
Sharpe Ratio
60 days
+3.22
120 days
+0.85
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+53.68%
3 years
+53.68%
5 years
+64.30%
Return-to-Drawdown Ratio
240 days
-0.44
3 years
+0.81
5 years
+0.11
Skewness
240 days
-0.87
3 years
+0.61
5 years
+0.19
Volatility
Realised Volatility
240 days
+57.66%
5 years
+51.63%
Standardised True Range
240 days
+3.81%
5 years
+2.70%
Downside Risk-Adjusted Return
120 days
+127.59%
240 days
+127.59%
Maximum Daily Upside Volatility
60 days
+69.42%
Maximum Daily Downside Volatility
60 days
+43.29%
Liquidity
Average Turnover Rate
60 days
+1.69%
120 days
+1.75%
5 years
--
Turnover Deviation
20 days
+9.39%
60 days
+27.22%
120 days
+31.14%
Peer Comparison
Healthcare Equipment & Supplies
Glaukos Corp
GKOS
8.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Glaukos Corp?
The TradingKey Stock Score provides a comprehensive assessment of Glaukos Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Glaukos Corp’s performance and outlook.
How do we generate the financial health score of Glaukos Corp?
To generate the financial health score of Glaukos Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Glaukos Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Glaukos Corp.
How do we generate the company valuation score of Glaukos Corp?
To generate the company valuation score of Glaukos Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Glaukos Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Glaukos Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Glaukos Corp.
How do we generate the earnings forecast score of Glaukos Corp?
To calculate the earnings forecast score of Glaukos Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Glaukos Corp’s future.
How do we generate the price momentum score of Glaukos Corp?
When generating the price momentum score for Glaukos Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Glaukos Corp’s prices. A higher score indicates a more stable short-term price trend for Glaukos Corp.
How do we generate the institutional confidence score of Glaukos Corp?
To generate the institutional confidence score of Glaukos Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Glaukos Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Glaukos Corp.
How do we generate the risk management score of Glaukos Corp?
To assess the risk management score of Glaukos Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Glaukos Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Glaukos Corp.
